Terms: = Bone cancer AND TOP2A, TOP2, TP2A AND Treatment
7 results:
1. Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome.
Trujillo-Paolillo A; Tesser-Gamba F; Seixas Alves MT; Filho RJG; Oliveira R; Petrilli AS; Toledo SRC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982681
[TBL] [Abstract] [Full Text] [Related]
2. The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity
Klausz K; Kellner C; Gehlert CL; Krohn S; Wilcken H; Floerkemeier I; Günther A; Bauerschlag DO; Clement B; Gramatzki M; Peipp M
Mol Cancer Ther; 2022 Jan; 21(1):70-78. PubMed ID: 34725192
[TBL] [Abstract] [Full Text] [Related]
3. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
[TBL] [Abstract] [Full Text] [Related]
4. treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract] [Full Text] [Related]
5. Clinical analysis of spinal stereotactic radiosurgery in the treatment of neurogenic tumors.
Shin DW; Sohn MJ; Kim HS; Lee DJ; Jeon SR; Hwang YJ; Jho EH
J Neurosurg Spine; 2015 Oct; 23(4):429-37. PubMed ID: 26140405
[TBL] [Abstract] [Full Text] [Related]
6. High top2B/top2a expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.
Song JH; Kweon SH; Kim HJ; Lee TH; Min WS; Kim HJ; Kim YK; Hwang SY; Kim TS
Br J Cancer; 2012 Jun; 107(1):108-15. PubMed ID: 22627319
[TBL] [Abstract] [Full Text] [Related]
7. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract] [Full Text] [Related]
